Abstract:Summary. The b-globin gene mutations and the a-globin genes of 620 patients with the phenotype of severe to moderate thalassaemia from seven centres in Sri Lanka were analysed. Twenty-four b-globin gene mutations were identified, three accounting for 84AE5% of the 1240 alleles studied: IVSI-5 (G fi C) 56AE2%; IVSI-1 (G fi A) 15AE2%; and haemoglobin E (codon (CD)26 GAG fi GAA) 13AE1%. Three new mutations were found; a 13-bp deletion removing the last nucleotide in CD6 to CD10 inclusively, IVSI-129 (A fi C) in t… Show more
“…Although mild β thalassemia mutations occur sporadically in some parts of Asia, and when inherited together with HbE give rise to a relatively mild phenotype, they are exceptionally rare in Sri Lanka; of over 40 β thalassemia mutations identified, only one is of the mild variety, and it has been found in only one patient (31). Thus the heterogeneity of the phenotype cannot be explained by the effect of a primary modifier.…”
Section: Phenotypic Diversitymentioning
confidence: 96%
“…First, there is the coinheritance of the mild form of α + thalassemia due to the loss of a single α gene, which occurs at a very high frequency right across the tropical belt (109). In Sri Lanka about 14% of the population carry this mutation (31), and if it is coinherited with HbE β thalassemia, it always produces a dramatic phenotypic change characterized by an extremely mild non-transfusion-dependent disease (70,85). The coinheritance of α thalassemia has also been found to cause a modest amelioration of the phenotype of some forms of β thalassemia and even sickle cell anemia, but the effect is nowhere near as dramatic as in HbE β thalassemia (109).…”
Although the inherited hemoglobin disorders were the first genetic diseases to be explored at the molecular level, they still have important messages for the future of medical genetics. In particular, they can offer a better understanding of the evolutionary and population biology of genetic disease, the mechanisms that underlie the phenotypic diversity of monogenic disease, and how, by developing appropriate partnerships, richer countries can help low-income countries to evolve programs for the control and management of these diseases where, in many cases, they are particularly common.
“…Although mild β thalassemia mutations occur sporadically in some parts of Asia, and when inherited together with HbE give rise to a relatively mild phenotype, they are exceptionally rare in Sri Lanka; of over 40 β thalassemia mutations identified, only one is of the mild variety, and it has been found in only one patient (31). Thus the heterogeneity of the phenotype cannot be explained by the effect of a primary modifier.…”
Section: Phenotypic Diversitymentioning
confidence: 96%
“…First, there is the coinheritance of the mild form of α + thalassemia due to the loss of a single α gene, which occurs at a very high frequency right across the tropical belt (109). In Sri Lanka about 14% of the population carry this mutation (31), and if it is coinherited with HbE β thalassemia, it always produces a dramatic phenotypic change characterized by an extremely mild non-transfusion-dependent disease (70,85). The coinheritance of α thalassemia has also been found to cause a modest amelioration of the phenotype of some forms of β thalassemia and even sickle cell anemia, but the effect is nowhere near as dramatic as in HbE β thalassemia (109).…”
Although the inherited hemoglobin disorders were the first genetic diseases to be explored at the molecular level, they still have important messages for the future of medical genetics. In particular, they can offer a better understanding of the evolutionary and population biology of genetic disease, the mechanisms that underlie the phenotypic diversity of monogenic disease, and how, by developing appropriate partnerships, richer countries can help low-income countries to evolve programs for the control and management of these diseases where, in many cases, they are particularly common.
“…The primary modifiers are the β thalassemia mutations of varying severity. Modifiers of this type turned out to be irrelevant in Sri Lanka because, of over 40 different β thalassemia mutations that have been identified, all but one are of the extremely severe variety (44). The secondary modifiers are those that involve the other globin gene loci.…”
Real innovations in medicine and science are historic and singular; the stories behind each occurrence are precious. At Molecular Medicine we have established the Anthony Cerami Award in Translational Medicine to document and preserve these histories. The monographs recount the seminal events as told in the voice of the original investigators who provided the crucial early insight. These essays capture the essence of discovery, chronicling the birth of ideas that created new fields of research; and launched trajectories that persisted and ultimately influenced how disease is prevented, diagnosed, and treated. In this volume, the Cerami Award Monograph is by David J Weatherall, Founder, Weatherall Institute of Molecular Medicine, Oxford University, John Radcliffe Hospital. A visionary in the field of hemoglobin, this is the story of Professor Weatherall's scientific journey.
“…Different classes of HBB mutations underlie betathalassemia, in descending order of frequency: missense/nonsense [25,26], splicing [27], regulatory [28], small or gross gene deletions [27,29], including the common deletion of the terminal portion of HBB [30], gene insertions [31], small insertion-deletions [32], and complex rearrangements [33]. In rare instances, the causative defect is due to a deletion of the LCR [18], mutations in another gene within [34] or outside [16] the beta-globin locus.…”
Beta-thalassemia is one of the most prevalent autosomal disorders in the world. Mutations in the HBB gene underlie deficiencies in hemoglobin production, which can interfere with oxygen delivery resulting in wide range of disease severity. Although >535 mutations have been characterized in the HBB gene, beta-thalassemia is broadly classified into three groups, based on clinical severity: beta-thalassemia major, beta-thalassemia intermedia and beta-thalassemia minor. In this article we review: 1) the molecular and biochemical basis of beta-thalassemia; 2) clinical features; 3) the range of common molecular variants of beta-thalassemia in a subset of geographic regions within the Indian Subcontinent and the Middle East; 4) potential molecular diagnostics; and 5) current and future treatments. We suggest that efforts to more completely characterize the HBB mutation distribution in high-risk areas, such as the Indian Subcontinent and the Middle East, may lead to improved diagnosis with earlier and more effective intervention strategies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.